Compare Las Vegas Sands Corp. (LVS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Revvity Inc — how do they compare? Las Vegas Sands Corp. trades at $36.2 (market cap $23.38B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and Revvity Inc for 12 Days on average.
| LVS | RVTY | |
|---|---|---|
Market Cap | $23.38B | $16.98B |
Volume | 6,994,661 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $157.36 |
52-Week Low | $35.81 | $82.26 |
Typical Hold Time | 72 Days | 12 Days |
Enterprise Value | $35.27B | $19.30B |
Dividend Yield | 3.32% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $36.15, up 0.95% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $13.02B in 2025 and a net income of $1.63B, with a P/E of 13.99 suggesting reasonable valuation. Recent news highlights Sands China's community initiatives and awards, while Q2 2026 earnings missed expectations.
The investment outlook is mixed: analyst consensus is bullish with a $59.78 price target, but high debt levels and a recent earnings miss pose risks. Upside potential exists if the company maintains revenue growth and executes its stock repurchase program, though sensitivity to Macao's tourism recovery and interest rates remains a key concern.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
